NCT00006013已完成2 期
Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 4
研究概览
简要总结
RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells.
PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.
详细描述
OBJECTIVES: I. Determine the response rate and response duration of patients with refractory or relapsed multiple myeloma treated with SU5416. II. Determine the toxicity of SU5416 in this patient population.
OUTLINE: This is a multicenter study. Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of unacceptable toxicity or disease progression. Patients are followed for survival.
PROJECTED ACCRUAL: A total of 20-38 patients will be accrued for this study within 2 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS: Histologically confirmed multiple myeloma with an elevated monoclonal protein in serum and/or urine No history of CNS lesion or CNS bleed
- •PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Cytopenias secondary to multiple myeloma involvement of bone marrow allowed Cytopenias not due to multiple myeloma require: WBC at least 3,000/mm3 Platelet count at least 75,000/mm3 Hepatic: Transaminases no greater than 2 times upper limit of normal Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance at least 50 mL/min Cardiovascular: No congestive heart failure, severe peripheral vascular disease, or significant arrhythmia No poorly controlled systolic or diastolic hypertension No uncompensated coronary artery disease No history of myocardial infarction or severe/unstable angina within past 6 months No known hypercoagulable state or deep venous or arterial thrombosis within past 3 months Pulmonary: No pulmonary embolism within past 3 months Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study No other severe medical or psychiatric condition (e.g., active peptic ulcer, active infection, or history of severe alcohol or drug abuse) No known hypersensitivity to paclitaxel or Cremophor
- •PRIOR CONCURRENT THERAPY: Biologic therapy: See Chemotherapy Chemotherapy: At least 1 but no more than 3 prior chemotherapy regimens Induction followed by high dose therapy with stem cell support considered a single treatment regimen Tandem courses of high dose therapy considered as 2 regimens Endocrine therapy: At least 1 prior regimen containing steroids Radiotherapy: Prior radiotherapy for symptom control allowed Surgery: At least 3 weeks since prior major surgery At least 1 year since prior coronary artery surgery, angioplasty, or stent placement No prior brain surgery Other: No other concurrent investigational drugs Concurrent bisphosphonates (e.g., pamidronate) allowed
排除标准
- 未提供
研究者
研究点 (4)
Loading locations...
相似试验
终止
2 期
SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedRecurrent MelanomaStage IV MelanomaNCT00006003National Cancer Institute (NCI)35
已完成
1 期
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation TherapyBrain and Central Nervous System TumorsNCT00004868Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
已完成
2 期
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and NeckCarcinoma of Unknown PrimaryHead and Neck CancerNon-melanomatous Skin CancerNCT00006361Memorial Sloan Kettering Cancer Center
已完成
1 期
SU5416 and Paclitaxel in Treating Patients With Advanced CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00006257City of Hope Medical Center
已完成
2 期
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney CancerKidney CancerNCT00006384City of Hope Medical Center